Relevant bibliographies by topics / Meldonium (mildronate)

Contents

  1. Journal articles
  2. Dissertations / Theses

Academic literature on the topic 'Meldonium (mildronate)'

Author: Grafiati
Published: 28 May 2022
Last updated: 30 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Meldonium (mildronate).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Meldonium (mildronate)"

1

Vertkin, A. L., N. O. Khovasova, V. V. Pshenichnikova, M. A. Alekseev, and A. U. Abdullaeva. "MELDONIUM: EFFECTIVE ACTION POINTS." Cardiovascular Therapy and Prevention 12, no. 2 (2013): 94–97. http://dx.doi.org/10.15829/1728-8800-2013-2-94-97.

Full text
Abstract:
The paper is focused on hypoxia and cell ischemia as universal pathogenetic mechanisms of disease development, which can be addressed by both etiotropic and pathogenetic therapy. The latter is represented by the so-called metabolic correctors. At present, one of the most widely used metabolic correctors is mildronate. The authors discuss the effectiveness of mildronate in various clinical situations and also present the relevant original findings.
APA, Harvard, Vancouver, ISO, and other styles
2

Jargin, Sergei V. "Meldonium (Mildronate): Primum nоn nocere". Pharmacological Research 114 (грудень 2016): 294. http://dx.doi.org/10.1016/j.phrs.2016.10.004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Greenblatt, H. Karl, and David J. Greenblatt. "Meldonium (Mildronate): A Performance-Enhancing Drug?" Clinical Pharmacology in Drug Development 5, no. 3 (2016): 167–69. http://dx.doi.org/10.1002/cpdd.264.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Tolstov, S. N., and V. B. Mychka. "Metabolic (cytoprotective) therapy of menopausal disturbances." Cardiovascular Therapy and Prevention 10, no. 3 (2011): 72–75. http://dx.doi.org/10.15829/1728-8800-2011-3-72-75.

Full text
Abstract:
The paper presents modern views on cardiovascular aspects of menopause and metabolic therapy of menopausal disturbances with meldonium (Mildronate®). The role of estrogen deficiency in climacteric disturbance development, key pathogenetic mechanisms of menopausal metabolic syndrome (MS), and relevant features of arterial hypertension and endothelial dysfunction development are discussed. The data on Mildronate® clinical use for cardiovascular prevention are summarized. The wide prevalence and multiple clinical manifestations of menopausal disturbances point to the need for their complex therap
APA, Harvard, Vancouver, ISO, and other styles
5

Ahmad, Asrar, Clemilson Berto-Junior, Papa Hoyeck, Namita Kumari, Marina Jerebtsova, and Sergei Nekhai. "Mildronate Ameliorates Kidney Function and Reduces Inflammation in SCD Mice." Blood 142, Supplement 1 (2023): 5274. http://dx.doi.org/10.1182/blood-2023-186459.

Full text
Abstract:
INTRODUCTION:Sickle cell disease (SCD) is a genetic hemoglobin disorder characterized by hemolytic anemia, vaso-occlusive crisis and inflammation that affects organs such as the kidney, liver, brain, spleen, and heart. SCD is driven by a mutation in the β-globin gene that causes sickling of red blood cells (RBCs). More than 50% of SCD patients are affected by chronic kidney diseases (CKD) and other comorbidities. Vasculopathy is caused by hemolysis-related endothelial dysfunction and inflammation, which collectively contribute to the development of renal disease. Mildronate (also known as Meld
APA, Harvard, Vancouver, ISO, and other styles
6

Berlato, Dener Gomes, and André Valle de Bairros. "Meldonium: Pharmacological, toxicological, and analytical aspects." Toxicology Research and Application 4 (January 1, 2020): 239784732091514. http://dx.doi.org/10.1177/2397847320915143.

Full text
Abstract:
Meldonium is the active molecule from Mildronate® with similar chemical structure to an amino acid, and it is known as (3-(2,2,2-trimethylhydrazine) propionate) (CAS 76144-81-5). This pharmaceutical substance is approved in Eastern Europe for cerebral and myocardial ischemia and has been on the World Doping Association’s banned substances list since January 2016. The goal of this review is to relate the use of meldonium as a doping agent, considering its pharmacological, toxicological, and analytical aspects. This review is based on the scientific literature from digital platforms. The main me
APA, Harvard, Vancouver, ISO, and other styles
7

Axmedov, Shamshod Jamshidovich. "EFFECTS OF THE DRUG MILDRONATE." Innovative Development in Educational Activities 2, no. 20 (2023): 40–59. https://doi.org/10.5281/zenodo.10047158.

Full text
Abstract:
<i>Mildronate (3-(2,2,2-trimethylhydrazine) propionate; THP; MET-88; meldonium, quaterine) is an anti-ischemic drug developed in the Latvian Institute of Organic Synthesis. Mildronate was designed as a promising inhibitor of carnitine biosynthesis aimed to prevent accumulation of cytotoxic intermediate products of fatty acid beta- oxidation in ischemic tissues and to block this highly oxygenconsuming process. Actually Mildronate is used in several countries in cardiology (treatment of chronic heart ischemic disease, stable angina pectoris, chronic heart failure, functional disorders of heart a
APA, Harvard, Vancouver, ISO, and other styles
8

Kuprash, Liana, Olena Kuprash, and Svetlana Gudarenko. "Metabolic cardiocytoprotectors (trimetazidine and trimethylhydrazine) in geriatrics. Short review." Issue 2 2022, no. 2 2022 (June 7, 2022): 63–70. http://dx.doi.org/10.47855/jal9020-2022-2-5.

Full text
Abstract:
The review presents the clinical studies results of the effectiveness of cardiocytoprotectors, fatty acids synthesis inhibitors, trimetazidine (preductal), and trimethylhydrazine (meldonium, mildronate) in the treatment of cardiovascular disease (angina pectoris, chronic heart failure) and the central nervous system disease (dyscirculatory encephalopathy, chronic cerebral insufficiency, stroke) various ages patients. These data indicate the prospects of using these drugs in the complex therapy of cardiovascular and cerebrovascular diseases in the geriatric clinic. Keywords: metabolic cardiocyt
APA, Harvard, Vancouver, ISO, and other styles
9

Horyn, Mariana, Marjan Piponski, Olha Poliak, Nataliia Shulyak, Marta Sulyma, and Liliya Logoyda. "Development of the spectrophotometric method for the determination of meldonium in capsules by using alizarine." ScienceRise: Pharmaceutical Science, no. 1(47) (February 29, 2024): 12–19. http://dx.doi.org/10.15587/2519-4852.2024.299165.

Full text
Abstract:
The aim of the work was to develop a simple, rapid, economic spectrophotometric method for the determination of meldonium in capsules based on the reaction with alizarin.&#x0D; Materials and methods. Analytical equipment: double-beam UV-visible spectrophotometer Shimadzu UV 1800 (Japan), a pair of 1 cm matched quartz cells, software UV-Probe 2.62, laboratory electronic balance RAD WAG AS 200/C, pH-meter И-160МИ. Pharmacopoeial standard sample (CRS) of meldonium dihydrate (Sigma-Aldrich, (≥ 98 %, HPLC)), alizarin (Synbias), capsules Metamax (Darnytsia) 250 mg, Vasopro (Farmak) 500 mg, Mildronat
APA, Harvard, Vancouver, ISO, and other styles
10

Litvinova, S. V., O. D. Ostroumova, A. I. Kochetkov, E. V. Mironova, and I. I. Sinitsyna. "Possibilities of using meldonium as part of complex therapy in patients with ischemic heart disease and chronic heart failure combined with obesity." Russian Journal of Cardiology and Cardiovascular Surgery 18, no. 1 (2025): 53. https://doi.org/10.17116/kardio20251801153.

Full text
Abstract:
Relevance. Cardiovascular diseases, including coronary heart disease (CHD), remain the leading causes of death worldwide. At the same time, concomitant obesity further increases the risk of adverse cardiovascular events (CVE) and complicates the management of these patients. One of the strategies aimed at increasing the effectiveness of CHD treatment is the use of metabolic therapy to ensure cardiocytoprotection. Aim. To study the effect of the drug Mildronate on the quality of life of patients with coronary heart disease and chronic heart failure (CHF) suffering from obesity. Material and met
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Meldonium (mildronate)"

1

Хабаль, О. В., та А. П. Симончук. "Ефективність мілдронату у хворих із хронічною серцевою недостатністю". Thesis, Сумський державний університет, 2017. http://essuir.sumdu.edu.ua/handle/123456789/54941.

Full text
Abstract:
Хронічна серцева недостатність(ХСН) це кінцева стадія багатьох захворювань серця. Повноцінна і адекватна терапія ХСН дозволяє зменшити вираженість клінічних проявів та покращити прогноз для життя пацієнта.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Meldonium (mildronate)' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography